Corrigendum to ‘Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial’

ISTH Academy, Faculty / Presenters, 4174036

“Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models”: comment

ISTH Academy, , 4174034

Integrative phosphoproteomic analyses reveal hemostatic-endothelial signaling interplay

ISTH Academy, Arie Hoogendijk, 4174030

Application of platelet transcriptomics for assessing treatment effectiveness and predicting long-term platelet counts recovery in aplastic anemia

ISTH Academy, Jun Shi, 4174028

Long-term FXa inhibition attenuates thromboinflammation after acute myocardial infarction and stroke by platelet proteome alteration

ISTH Academy, , 4174026

Guidelines and guidance: what is the path forward for the ISTH?

ISTH Academy, James Douketis, 4151470

Deconstructing fibrin(ogen) structure

ISTH Academy, Nathan Hudson, 4151471

Splanchnic vein thrombosis: management for the thrombosis specialist

ISTH Academy, Kenneth Bauer, 4151476

Thrombotic complications in pregnancy: a case-based review of the evidence

ISTH Academy, Faculty / Presenters, 4151477

Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production

ISTH Academy, Glaivy Batsuli, 4151479

Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery

ISTH Academy, Joseph Palumbo, 4151483

Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding

ISTH Academy, Faculty / Presenters, 4151486

Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease

ISTH Academy, Patricia Maguire, 4151487

Mechanistic basis of activation and inhibition of protein disulfide isomerase by allosteric antithrombotic compounds

ISTH Academy, Nicola Pozzi, 4151491

Risk assessment and management strategies in older patients with acute pulmonary embolism

ISTH Academy, , 4151492

Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study

ISTH Academy, Faculty / Presenters, 4151493

Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years

ISTH Academy, Faculty / Presenters, 4151498

Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE

ISTH Academy, Faculty / Presenters, 4151499

Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study

ISTH Academy, Flora Peyvandi, 4151503

Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document

ISTH Academy, Michelle Sholzberg, 4151506

“Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models”: comment

ISTH Academy, , 4151508

Identification of hemodynamically stable patients with acute pulmonary embolism at high risk for death: external validation of different models

ISTH Academy, Faculty / Presenters, 4151509

Annoucements

ISTH Academy, Faculty / Presenters, 4151511

Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trial

ISTH Academy, Faculty / Presenters, 4174021

Machine learning models for risk prediction of cancer-associated thrombosis: a systematic review and meta-analysis

ISTH Academy, , 4174020

Risk assessment and management strategies in older patients with acute pulmonary embolism

ISTH Academy, , 4174018

Mechanistic basis of activation and inhibition of protein disulfide isomerase by allosteric antithrombotic compounds

ISTH Academy, Nicola Pozzi, 4174017

Validating International Classification of Diseases Code 10th Revision algorithms for accurate identification of pulmonary embolism

ISTH Academy, Faculty / Presenters, 4174015

Biophysical characterization of blood coagulation factor VIII binding to lipid nanodiscs that mimic activated platelet surfaces

ISTH Academy, P. Clint Spiegel, 4174011

Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery

ISTH Academy, Joseph Palumbo, 4174009

Thrombotic complications in pregnancy: a case-based review of the evidence

ISTH Academy, Faculty / Presenters, 4174003

A rare case of factor X deficiency induced by valproic acid

ISTH Academy, Faculty / Presenters, 4168908

Thrombotic microangiopathic anemia in patients with sickle cell disease and its variants during a vaso-occlusive crisis

ISTH Academy, Faculty / Presenters, 4168907

Fibrinogen levels and bleeding risk in adult extracorporeal cardiopulmonary resuscitation: multicenter observational study subanalysis

ISTH Academy, Faculty / Presenters, 4168906

Persisting thrombomodulin resistance at 3 months after liver transplantation in children with cirrhosis

ISTH Academy, Faculty / Presenters, 4168905

Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study

ISTH Academy, Faculty / Presenters, 4168903

Exercise capacity, dyspnea, and quality of life 6 months after exercise-based rehabilitation in patients with persistent dyspnea following pulmonary embolism

ISTH Academy, Faculty / Presenters, 4168902

Association between genetic risk and adherence to the Dietary Approaches to Stop Hypertension diet for developing venous thromboembolism

ISTH Academy, , 4168899

Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis—findings from the ONCO DVT Study

ISTH Academy, Faculty / Presenters, 4168896

Efficacy and safety of plasma-derived von Willebrand factor/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease – WIL-31 study post hoc analysis

ISTH Academy, Faculty / Presenters, 4168893

Exploration of the plasma proteomic profile of patients at risk of thromboembolic events

ISTH Academy, Maartje van den Biggelaar, 4168892

Protofibril packing density of individual fibers alters fibrinolysis

ISTH Academy, , 4168890

Comparison of 7 artificial intelligence models in predicting venous thromboembolism in COVID-19 patients

ISTH Academy, Deepa Arachchillage, 4168889

Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer

ISTH Academy, Faculty / Presenters, 4168885

Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study

ISTH Academy, Faculty / Presenters, 4168884

Major bleeding and thromboembolic complications associated with antithrombotic treatment in patients with atrial fibrillation/flutter and incident cancer

ISTH Academy, Faculty / Presenters, 4168882

Extravascular factor IX after gene therapy in hemophilia B, does it matter?

ISTH Academy, , 4168880

High preoperative D-dimer increases the risk of venous thromboembolism after gynecological tumor surgeries: a meta-analysis of cohort studies

ISTH Academy, , 4168877

Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies?

ISTH Academy, Ben Samelson-Jones, 4168873

Hemophilia treatments and the paradox of choice

ISTH Academy, , 4168872

Anticoagulation in Patients with Chronic Kidney Disease

ISTH Academy, Faculty / Presenters, 4150727

Adeno-associated virus-based gene therapy for hemophilia–addressing the gaps

ISTH Academy, , 4158551

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?

ISTH Academy, Isabelle Mahé, 4158552

Challenges and considerations of genetic testing in von Willebrand disease

ISTH Academy, Flora Peyvandi, 4158554

A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors

ISTH Academy, Faculty / Presenters, 4158555

Contemporary approaches to treat people with hemophilia: what’s new and what’s not?

ISTH Academy, Faculty / Presenters, 4158556

Andexanet alfa: trials just leave us with more questions

ISTH Academy, Richard Buka, 4158557

Extending health equity to people with moderate and mild hemophilia A: revisiting the HAVEN 6 trial

ISTH Academy, Faculty / Presenters, 4158558

Should a history of venous thromboembolism be considered a contraindication for scuba diving?

ISTH Academy, Nicolas Gendron, 4158559

Reduced- versus full-dose anticoagulants for the extended treatment of cancer-associated venous thromboembolism in Thai patients

ISTH Academy, Kochawan Boonyawat, 4158560

Validation of the 5-SNP score for the prediction of venous thromboembolism in a Danish fast-track cohort of 6789 total hip and total knee arthroplasty patients

ISTH Academy, Faculty / Presenters, 4158561

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial

ISTH Academy, Runhui Wu, 4158562

Type of D-dimer assay determines the diagnostic yield of computed tomography in patients suspected for pulmonary embolism

ISTH Academy, , 4158563

Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study

ISTH Academy, , 4158565

Immune tolerance induction for inhibitor eradication in nonsevere hemophilia A: a case series

ISTH Academy, Faculty / Presenters, 4158597

Acquired factor V inhibitor in a case of pediatric venous thrombosis

ISTH Academy, Faculty / Presenters, 4158598

Clinical management of bleeding manifestations in a family with the thrombomodulin C1611>A (p.Cys537Stop) mutation

ISTH Academy, Faculty / Presenters, 4158599

Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura

ISTH Academy, , 4158600

Structural bioinformatics for rational drug design

ISTH Academy, Kanin Wichapong, 4158549

Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies

ISTH Academy, Ingrid Pabinger, 4158548

Transfusion in trauma: empiric or guided therapy?

ISTH Academy, Nicola Curry, 4158547

Thromboprophylaxis in multiple myeloma

ISTH Academy, Laurent Frenzel, 4158546

Venous thromboembolism still leads on maternal death

ISTH Academy, Sue Pavord, 4158545

Mini-clusters of postadenovirus VITT

ISTH Academy, Theodore (Ted) Warkentin, 4158544

The detrimental impact of ferritin “normal” ranges on diagnosis of bleeding disorders in women

ISTH Academy, Grace Tang, 4158543

Annoucements

ISTH Academy, Faculty / Presenters, 4151550

Recommendations for defining disturbed flow as laminar, transitional, or turbulent in assays of hemostasis and thrombosis: communication from the ISTH SSC Subcommittee on Biorheology

ISTH Academy, Faculty / Presenters, 4151549

2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase–based antiphospholipid antibody domain—collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non–enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibod

ISTH Academy, Faculty / Presenters, 4151548

Antiproliferative agent attenuates postthrombotic vein wall remodeling in murine and human subjects

ISTH Academy, , 4151547

High-dose intravenous immunoglobulin G and usual heparin anticoagulation for urgent cardiac surgery in a patient with severe autoimmune heparin-induced thrombocytopenia

ISTH Academy, Faculty / Presenters, 4151546

A gain of function variant in RGS18 candidate for a familial mild bleeding syndrome

ISTH Academy, Marie-Christine Alessi, 4151545

Genetic engineering of megakaryocytes from blood progenitor cells using messenger RNA lipid nanoparticles

ISTH Academy, Christian Kastrup, 4151544

A novel role for thioredoxin-related transmembrane protein TMX4 in platelet activation and thrombus formation

ISTH Academy, Yi Wu, 4151542

Thrombocytopenia developed in intensive care unit for congenital heart disease: incidence, risk factors, and outcomes

ISTH Academy, , 4151541

Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome

ISTH Academy, Cihan Ay, 4151540

Critical role for platelet Ral GTPases in regulating venous thrombosis in mice

ISTH Academy, Alastair Poole, 4151539

Impact of limited language proficiency on participation in venous thromboembolism research: a retrospective analysis

ISTH Academy, Yan Xu, 4151538

Association of primary and secondary hemostasis biomarkers with acute ischemic stroke outcome in patients undergoing thrombectomy, with or without thrombolytics: post hoc analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands-NO IV

ISTH Academy, Moniek de Maat, 4151537

Management and outcomes in patients with tumor thrombus: a retrospective cohort study

ISTH Academy, Tzu-Fei Wang, 4151534

Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study

ISTH Academy, Faculty / Presenters, 4151533

Incidence and risk factors for postthrombotic syndrome in neonates and children in a single-center cohort study

ISTH Academy, Faculty / Presenters, 4151532

Loss of function in protein Z (PROZ) is associated with increased risk of ischemic stroke in the UK Biobank

ISTH Academy, Pavan Bendapudi, 4151531

Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism

ISTH Academy, Sameer Parikh, 4151529

Circulating tumor DNA predicts venous thromboembolism in patients with cancers

ISTH Academy, Ang Li, 4151528

Alterations in visible light exposure modulate platelet function and regulate thrombus formation

ISTH Academy, Faculty / Presenters, 4151527

Annoucements

ISTH Academy, Faculty / Presenters, 4151233

Recommendations for defining disturbed flow as laminar, transitional, or turbulent in assays of hemostasis and thrombosis: communication from the ISTH SSC Subcommittee on Biorheology

ISTH Academy, Faculty / Presenters, 4151232

2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase–based antiphospholipid antibody domain—collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non–enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibod

ISTH Academy, Faculty / Presenters, 4151231

Antiproliferative agent attenuates postthrombotic vein wall remodeling in murine and human subjects

ISTH Academy, , 4151230

Gene therapy in hemophilia: the dawn of a new era

ISTH Academy, Flora Peyvandi, 4158550